- Home
- BHVN vs ECAT Comparison
BHVN vs ECAT Comparison
Compare BHVN & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHVN
- ECAT
- Stock Information
- Founded
- BHVN 2013
- ECAT 2021
- Country
- BHVN United States
- ECAT United States
- Employees
- BHVN N/A
- ECAT N/A
- Industry
- BHVN Biotechnology: Pharmaceutical Preparations
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- BHVN Health Care
- ECAT Finance
- Exchange
- BHVN Nasdaq
- ECAT Nasdaq
- Market Cap
- BHVN 1.9B
- ECAT 1.6B
- IPO Year
- BHVN 2017
- ECAT N/A
- Fundamental
- Price
- BHVN $16.52
- ECAT $16.43
- Analyst Decision
- BHVN Strong Buy
- ECAT
- Analyst Count
- BHVN 14
- ECAT 0
- Target Price
- BHVN $49.23
- ECAT N/A
- AVG Volume (30 Days)
- BHVN 2.1M
- ECAT 278.6K
- Earning Date
- BHVN 11-11-2025
- ECAT 01-01-0001
- Dividend Yield
- BHVN N/A
- ECAT 9.20%
- EPS Growth
- BHVN N/A
- ECAT N/A
- EPS
- BHVN N/A
- ECAT 2.39
- Revenue
- BHVN N/A
- ECAT N/A
- Revenue This Year
- BHVN N/A
- ECAT N/A
- Revenue Next Year
- BHVN $2,079.03
- ECAT N/A
- P/E Ratio
- BHVN N/A
- ECAT $7.15
- Revenue Growth
- BHVN N/A
- ECAT N/A
- 52 Week Low
- BHVN $12.79
- ECAT $14.02
- 52 Week High
- BHVN $54.98
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- BHVN 54.24
- ECAT 53.19
- Support Level
- BHVN $16.30
- ECAT $16.02
- Resistance Level
- BHVN $18.18
- ECAT $16.70
- Average True Range (ATR)
- BHVN 1.26
- ECAT 0.19
- MACD
- BHVN 0.02
- ECAT -0.00
- Stochastic Oscillator
- BHVN 55.52
- ECAT 63.20
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.